COMMUNIQUÉS West-GlobeNewswire

Scythian Biosciences Corp. Announces Results of Special Meeting of Shareholders and Grant of Options and DSUs
09/03/2018
TORONTO, March 09, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the " Company " or “ Scythian ”) (TSX-V: SCYB ) (Frankfurt: 9SB ) (OTC – Nasdaq Intl:SCCYF) is pleased to announce the results of its special [...]
Teladoc to Participate in Upcoming Investor Conferences
09/03/2018
PURCHASE, NY, March 09, 2018 (GLOBE NEWSWIRE) -- Teladoc , Inc. (NYSE: TDOC ), the world’s largest and most trusted provider of virtual care delivery services, announced today that Mark Hirschhorn, chief operating [...]
Crown Bioscience to Showcase Scientific Expertise at Cambridge UK Symposium: Preclinical Evaluation of Novel Immunotherapies
09/03/2018
SAN DIEGO, March 09, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing [...]
Aclaris Therapeutics Announces Issuance of U.S. Patent Covering a JAK Inhibitor for Treating Hair Loss Disorders
09/03/2018
Issuance of U.S. Patent No. 9,895,301 Further Bolsters Aclaris’ Intellectual Patent Portfolio WAYNE, Pa., March 09, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS ), a dermatologist-led, [...]
Vericel to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference
09/03/2018
CAMBRIDGE, Mass., March 09, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL ), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Gerard Michel, [...]
Exalenz Bioscience to Participate in Upcoming Investor Conferences
09/03/2018
MODI’IN, Israel and MANASQUAN, N.J., March 09, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE: EXEN ), a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of [...]
Stealth Mark Joins the Industry Council for Tangible Assets and its Anti-Counterfeiting Task Force
09/03/2018
HOFFMAN ESTATES, IL , March 09, 2018 (GLOBE NEWSWIRE) -- Wellness Center USA, Inc. (OTCQB: WCUI ) is pleased to announce that its wholly-owned subsidiary, StealthCo, Inc., dba Stealth Mark, has joined the Industry [...]
Arch Biopartners Closes $1.25M Non-Brokered Private Placement Financing
09/03/2018
TORONTO, March 09, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) and (OTCBB: ACHFF ), announced today it has closed the non-brokered private placement the Company disclosed in [...]
VBL Therapeutics to Report Fiscal 2017 Results on March 15
09/03/2018
TEL AVIV, Israel, March 09, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for [...]
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
09/03/2018
DUBLIN, Ireland, March 09, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq AVDL), “Avadel” or “the Company,” today announced that management will present at two upcoming investor conferences: The 30 th [...]
Projecting a Per Share Price Target of $1.25, PotNetwork Holding Inc. Highlighted as “Strong Speculative Buy” in Research Initiated by Harbinger Research, LLC
09/03/2018
FT LAUDERDALE, Fla., March 09, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- PotNetwork Holding, Inc. (OTC Pink:POTN ) (“Company”) is pleased to announce today that PotNetwork the Company and Diamond CBD have been the [...]
Orphazyme to Present at Cowen & Co. 38th Annual Health Care Conference
09/03/2018
Orphazyme A/S Investor news No. 04/2018 Copenhagen, March 9, 2018 – Orphazyme A/S , a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that Anders [...]
Sonoma Pharmaceuticals to Present at Roth Capital Partners 30th Annual Growth Stock Conference on March 13, 2018
09/03/2018
PETALUMA, Calif., March 09, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA, Warrants – SNOAW) today announced that Jim Schutz, Sonoma CEO, will be a featured presenter at the Roth Capital Partners [...]
Voyager Therapeutics Announces Longer-Term Data from Ongoing Phase 1b Trial of VY-AADC for Advanced Parkinson’s Disease
09/03/2018
Robust and durable improvements in patients' motor function achieved with substantial reductions in use of daily oral levodopa and other Parkinson’s disease medications; one-time administrations of VY-AADC well- [...]
ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update
09/03/2018
Pipeline Achievements in 2017 Included Progress with Three Phase 3 and Two Phase 2 Clinical Trials -Key 2018 Clinical Milestones Anticipated for All Three Development Compounds Lead Compound OBE2109 Endometriosis Phase [...]
FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the directed share issue without payment to the Company itself
09/03/2018
FIT Biotech Oy Company release March 9, 2018 at 2.00 pm EET FIT Biotech Oy's Board of Directors has decided on the directed share issue without payment to the Company itself FIT Biotech Oy's Board of Directors has [...]
MacroGenics to Present at Cowen Health Care Conference
09/03/2018
Rockville, MD, March 09, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]
Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results on March 15, 2018
09/03/2018
FREMONT, Calif., March 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:ST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated [...]
Trillium Therapeutics Reports Annual 2017 Financial and Operating Results
09/03/2018
Presented evidence of clinical activity and good tolerability from both TTI-621 trials at ASH Received FDA clearance to proceed with second clinical CD47 program, TTI-622 Cash and marketable securities of $81.8 million [...]

Pages